Pharmacology/Pharmaceutical Industry
[Abstract Only] More than a third of older adults are prescribed potentially inappropriate drugs, study finds
6 Nov, 2020 | 09:42h | UTCOriginal study: Potentially Inappropriate Medications Are Associated with Increased Healthcare Utilization and Costs – Journal of the American Geriatrics Society (link to abstract – $ for full-text)
Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Efficacy, duration of protection, and percentage of the population receiving the vaccine are key issues
5 Nov, 2020 | 09:09h | UTCChallenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination – The Lancet
Commentary on Twitter
The real deal herd immunity, via a #SARSCoV2 vaccine, will be a formidable feat to achieve, with efficacy, coverage levels and duration of protection as key determinants https://t.co/3jeXkO5Yak @TheLancet pic.twitter.com/mXcDpHbHR6
— Eric Topol (@EricTopol) November 5, 2020
Review: Clinical Management of Hyperkalemia. Classification and monitoring, when to reinitiate RAASi therapy, use oral K+-binding agents, and more
5 Nov, 2020 | 08:58h | UTCClinical Management of Hyperkalemia – Mayo Clinic Proceedings
Systematic Review: Little benefit from phlebotonics in patients with venous insufficiency
5 Nov, 2020 | 08:54h | UTCPhlebotonics for venous insufficiency – Cochrane Library
[Abstract Only] Randomized, open-label trial: Olanzapine seems effective for the prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy
5 Nov, 2020 | 08:48h | UTCOlanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
RCT of adding Olanzapine to Nausea regimen (aprepitant, ondan, dex)
231 children, cycle 1 of highly emetogenic chemo
Primary endpoint: complete response= no vomiting + no rescue med use
78% v 59% day 1
74% v 47% days 1-5
64% v 38% overall#supponc https://t.co/cZFM8bLXKg— Arjun Gupta (@guptaarjun90) September 16, 2020
Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Dosage, timing of initiation, mode of administration, duration of therapy, infection surveillance, tapering, and more
5 Nov, 2020 | 08:45h | UTC
Commentary on Twitter
Glucocorticoids in #ARDS… focus not only on molecule! Key elements to achieve optimal response to therapy:
➡️ dosage (initial, overtime, adjustments)
➡️ timing of initiation
➡️ mode of administration
➡️ duration of therapy
➡️ tapering
➡️ co-interventionshttps://t.co/4b9vtNXsb7 pic.twitter.com/X6UZyMSI1r— Intensive Care Medicine (@yourICM) November 4, 2020
Randomized trial: Vitamin C does not improve iron absorption in adult patients with iron deficiency anemia
4 Nov, 2020 | 09:42h | UTCCommentary: Study: Vitamin C Supplements Have No Effect on Iron-Deficiency Anemia – NEJM Journal Watch
Commentary on Twitter
RCT finds oral iron alone is equivalent to oral iron + #vitaminC in improving hemoglobin and iron absorption in patients with iron deficiency #anemia https://t.co/atSVVnGkEV #VisualAbstract
— JAMA Network Open (@JAMANetworkOpen) November 2, 2020
Review: Contraceptive challenges in women with common medical conditions
4 Nov, 2020 | 09:22h | UTCContraceptive Challenges in Women With Common Medical Conditions – Mayo Clinic Proceedings
Spike in prescribing dexamethasone to Covid-19 patients may do more harm than good
3 Nov, 2020 | 03:11h | UTCSpike in prescribing dexamethasone to Covid-19 patients may do more harm than good – STAT
Perspective: A series of disappointing results of immune-based therapies for COVID-19
3 Nov, 2020 | 03:13h | UTCA Series of Disappointing Results of Immune-Based Therapies for COVID-19 – HIV and ID Observations
Opinion – Hydroxychloroquine: A tale of overzealous optimism and patient harm
3 Nov, 2020 | 03:09h | UTCHydroxychloroquine: A tale of overzealous optimism and patient harm – First10EM
[Abstract Only] Cohort study: Sodium–Glucose Cotransporter-2 Inhibitors and the risk for diabetic ketoacidosis
3 Nov, 2020 | 03:01h | UTCCommentarios: Can You Spot Euglycemic DKA From SGLT-2 Inhibitors? – Journal Feed AND Sodium glucose cotransporter-2 inhibitor use associated with increased risk of diabetic ketoacidosis – 2 Minute Medicine
WHO Q & A: COVID-19 Vaccines
2 Nov, 2020 | 02:38h | UTCCoronavirus disease (COVID-19): Vaccines – World Health Organization
Regeneron: Independent committee recommends holding trial enrollment in hospitalized patients with high oxygen requirements
2 Nov, 2020 | 02:31h | UTC
Commentary on Twitter
More potential evidence against antibody drugs late in course of #COVID19: Regeneron says independent cmte has recommended not enrolling pts on high oxygen into trial "based on a potential safety signal and an unfavorable risk/benefit profile at this time" https://t.co/moHtuhV9cP
— Meg Tirrell (@megtirrell) October 30, 2020
Scientists warn Americans are expecting too much from a vaccine
2 Nov, 2020 | 02:25h | UTCScientists Warn Americans Are Expecting Too Much From a Vaccine – Kaiser Health News
Meta-analysis: Comparison of acetaminophen with ibuprofen for treatment of fever or pain in children younger than 2 years
2 Nov, 2020 | 02:21h | UTC
Commentary on Twitter
Systematic review & meta-analysis finds use of ibuprofen vs acetaminophen for the treatment of fever or pain in children <2 years was associated with reduced temperature and less pain within the first 24 hours of treatment, with equivalent safety. https://t.co/Kl08IhwJKN
— JAMA Network Open (@JAMANetworkOpen) October 30, 2020
Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease
2 Nov, 2020 | 02:18h | UTC
Randomized trial: Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions
2 Nov, 2020 | 02:17h | UTC
It may be time to reset expectations on when we’ll get a Covid-19 vaccine
30 Oct, 2020 | 01:10h | UTCIt may be time to reset expectations on when we’ll get a Covid-19 vaccine – STAT
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
30 Oct, 2020 | 01:14h | UTCThe ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug – Science
Commentaries on Twitter
Remdesivir, despite failing in Solidarity trial, received FDA approval without input from outside advisory group. EU cut pricing deal with Gilead without knowing Solidarity data. @kakape and I explain in "The ‘very, very bad look’ of remdesivir" https://t.co/yTKq2A1WQT pic.twitter.com/NhBLum09VG
— Jon Cohen (@sciencecohen) October 28, 2020
Uncovering a scandal about Gilead and Remdesivir
Deep reporting by @sciencecohen and @kakape @ScienceMagazine
The company knew the #SOLIDARITY trial data well before it its preprint. And so did the FDA before giving a full approval, w/o external review https://t.co/4REMEwTvc5— Eric Topol (@EricTopol) October 28, 2020
Opinion: For now, it’s unethical to use human challenge studies for SARS-CoV-2 vaccine development
30 Oct, 2020 | 01:09h | UTC
Study provides new estimates of breast cancer risks associated with different hormone replacement therapy preparations
30 Oct, 2020 | 01:04h | UTCCommentaries: Study provides new estimates of breast cancer risks associated with HRT – University of Oxford AND New estimates of breast cancer risks associated with HRT – The BMJ AND HRT: Breast Ca Risk Tied to Hormone Type, Duration of Tx – Physician’s Weekly
Randomized phase 2 trial: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
29 Oct, 2020 | 09:16h | UTCAudio Interview: A New Monoclonal Antibody for Covid-19 – New England Journal of Medicine
Commentaries on Twitter
BLAZE-1🔥 – outpatient trial of LY-Cov555, mAb recently dropped from ACTIV-3 inpatient trial
Only 1 of the 3 mAb dosages (middle one 🤷♂️) ⬇️ VL by d11
mAb assoc with modest ⬇️ in healthcare visits (1.6% vs 6.3% for placebo)
😑 Far from a game changerhttps://t.co/zZMGlodaaF pic.twitter.com/ofs1UgN1ZA
— Ilan Schwartz is on🦋 (@GermHunterMD) October 28, 2020
Phase 2 Lilly #SARSCoV2 monoclonal antibody outpatient trial just published @NEJM
The lack of a dose response for viral load reduction +modest effects on symptoms do not make this look like a potent intervention https://t.co/oyRG8fUNHf pic.twitter.com/uobuCIznmD— Eric Topol (@EricTopol) October 28, 2020
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
29 Oct, 2020 | 09:09h | UTC
Commentary on Twitter
NEW—What defines an efficacious #COVID19 vaccine? Experts @JennerInstitute@OxfordVacGroup @OxPrimaryCare & @OxfordBRC outline key challenges for assessing clinical efficacy of vaccines against SARS-CoV-2 @TheLancetInfDis https://t.co/QsLnLdUiYE pic.twitter.com/skpb0rfSdF
— The Lancet (@TheLancet) October 28, 2020
Randomized trial: Osimertinib in resected EGFR-Mutated non–small-cell lung cancer
29 Oct, 2020 | 09:04h | UTCOsimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer – New England Journal of Medicine